Gilead Sciences

GILD · NASDAQ · USD

$149.05−1.47%−$2.23

Close · September 30, 2026

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue7,8036,9607,9257,7697,0826,6677,5697,5456,9546,6867,1147,050
Cost of revenue1,5791,4451,6201,5691,5011,5401,5811,5741,5441,5521,5601,565
Gross profit6,2245,5156,3056,2005,5815,1275,9885,9715,4105,1345,5545,485
Selling, general and administrative1,9061,4261,7771,3521,3581,2221,8611,4101,3691,3621,5801,315
Research and development1,6901,3551,5661,3341,4501,3391,6121,3851,3481,4701,4511,459
Operating income2,6282,7342,9623,5142,7732,5662,5153,1762,6932,3022,5232,711
EBIT2,6282,7342,9623,5142,7732,5662,5153,1762,6932,3022,5232,711
EBITDA3,3263,4233,6494,2003,4643,2623,2083,8663,3872,9923,2113,395
Interest expense247240255256254260249238237254252232
Pre-tax income-10,2542,5802,0783,6412,4281,6492,1689562,052-4,4851,6542,318
Income tax242559-105589468334385-297438-315237146
Net income-10,4962,0212,1833,0521,9601,3151,7831,2531,614-4,1701,4292,180
Net income to common shareholders-10,4962,0212,1833,0521,9601,3151,7831,2531,614-4,1701,4292,180
Basic EPS-8.441.631.762.461.571.061.431.001.29-3.341.151.75
Diluted EPS-8.451.611.742.431.561.041.411.001.29-3.341.131.73
Average shares (basic)1,2431,2421,2421,2431,2451,2461,2481,2471,2471,2471,2481,248
Average shares (diluted)1,2431,2541,2531,2541,2551,2591,2591,2541,2511,2471,2561,257
Dividend per share0.820.820.790.790.790.790.770.770.770.770.750.75